Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
To guide our collaborative, globe-spanning alliance, GA4GH relies on a Standards Steering Committee and an Executive Committee.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across four Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Solve your real-world data problems with support from this valuable network of global institutions.
Work with like-minded groups committed to better data use in areas like rare disease, cancer, and infectious disease.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
26 Sep 2018
A new resource developed by the Variant Interpretation for Cancer Consortium (VICC), a GA4GH Driver Project, makes clinical interpretation of variants much more consistent by aggregating known information about mutations associated with non-hereditary cancer.
When a patient is diagnosed with or dealing with later stages of cancer, her clinicians need to understand her unique cancer variants to determine the best course of treatment.
A new resource developed by the Variant Interpretation for Cancer Consortium (VICC), a GA4GH Driver Project, makes this clinical exercise much more consistent by aggregating known information about mutations associated with non-hereditary cancer.
The VICC Meta-Knowledgebase aggregates cancer variant interpretations from six distinct resources that contain clinical information related to specific variants or “knowledgebases”: Cancer Genome Interpreter (CGI), Clinical Interpretations of Variants in Cancers (CIViC), Jackson Labs Clinical Knowledgebase (JAX-CKB), MolecularMatch, OncoKB, and the Precision Medicine Knowledgebase (PMKB).
“The new resource serves as a kind of translator so that all of these knowledgebases can be searched simultaneously and their results presented in a common language,” said Obi Griffith, assistant director of the McDonnell Genome Institute (MGI) at Washington University School of Medicine in St. Louis and one of three senior authors on a paper about the resource published on BioRxiv in July. Together with his twin brother Malachi, Obi leads the Griffith Lab which maintains the CIViC knowledgebase.
According to the Wellcome Sanger Institute’s Cancer Gene Census, more than 700 genes have been associated with cancer to date, and 90 percent of these contain mutations that are somatic (not passed down between generations). Unlike BRCA1 and BRCA2, two commonly known genes associated with familial risk of breast and ovarian cancer, somatic mutations are spontaneous, unrelated to one’s family history and specific to an individual’s cancer cells.
Hundreds of thousands of different mutations, or “variants”, in non-hereditary cancer genes have been identified and reported in databases like COSMIC, but only a small fraction of these variants are known to cause disease — the rest are dubbed “variants of uncertain significance,” or VUS, and being told you carry one of these mutations provides no insight into the causes and best treatment options for your disease.
“Distinguishing the VUSs from variants that are pathogenic (disease-causing) or predict patient outcomes or treatment responses is critical to providing effective care to cancer patients and those at risk of developing disease,” said Malachi Griffith, MGI Assistant Director and another senior author on the paper. But the world of cancer variation classification is a fragmented one, and hundreds of siloed efforts have sprung up around the globe to collate information from clinicians and researchers about whether any particular variant is worthy of concern.
But until the work of the VICC, none of these knowledgebases spoke the same language. Due to differences in the data structure, curation strategy, and primary literature used by each, curated knowledge is represented differently from one knowledgebase to the next. In practice, generating a consensus report across knowledgebases requires interpretation “polyglots” to assimilate the information from each resource into a cohesive summary. The training, skill, and effort required to perform this translation scales poorly as the number of knowledgebases continues to expand.
“This is a space that is still in the process of being defined,” said Alex Wagner, a post-doctoral fellow in the Griffith Lab and first author on the paper. “For years, each clinical site has been curating literature describing clinical interpretations of genetic variants and building their own knowledgebases to represent them, without clearly defined standards by which they should represent these data. Relevant standards and resources have only recently emerged, and are still rapidly developing.”
The VICC meta-knowledgebase represents an unprecedented framework for structuring and harmonizing clinical interpretations across the world’s knowledge of cancer-related genetic variation.
“We relied on established community resources, standards, and guidelines to transform the data from each knowledgebase into a consistent vocabulary,” said Wagner. “This involves connecting curated knowledgebases through custom-defined rules for translating data from each resource. As a result, we have consolidated interpretations into a single, harmonized open-access meta-knowledgebase that contains 12,856 harmonized interpretations supported by 4,354 distinct publications.”
“This work was a few years in the making, and is ongoing,” said Wagner, who noted that the six knowledge bases currently aggregated by the VICC meta-knowledgebase represent some of the world’s preeminent publicly accessible knowledge on clinical interpretations of non-hereditary cancer variants. “But there are also a multitude of knowledge bases from academic and clinical centers that are not publicized, but would likely benefit from adopting the harmonization framework we outline in our work.” The team is encouraging institutions that maintain such resources to participate in the VICC to increase global consensus of the clinical relevance of each variant and improve cancer care around the world.